Neuren: U.S. Army to lead Glypromate study in brain injury

By Lisa Kerner

Charlotte, N.C., Sept. 5 - Neuren Pharmaceuticals said in mid-2007, physicians at the U.S. Army Medical Center in Tacoma, Wash., will conduct a phase 2 safety and efficacy study of Glypromate in reducing brain injury caused by cardiac arrest while not in the hospital.

Results from the planned investigator-led study will be used in the submission of an Investigational New Drug application by the Army researchers.

Neuren, based in Auckland, New Zealand, will supply the drug product for the study, as well as preclinical, clinical and regulatory documents for regulatory filings.

The biotechnology company said it will retain all commercial rights to Glypromate in the studied indications.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.